{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:20Z","timestamp":1786988120021,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejpb.2022.10.005","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:27:28Z","timestamp":1665556048000},"page":"260-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation"],"prefix":"10.1016","volume":"180","author":[{"given":"Bishal","family":"Raj Adhikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhra","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pletzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Lamont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamal C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.10.005_b0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-018-0630-8","article-title":"Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis","volume":"18","author":"Sch\u00e4fer","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejpb.2022.10.005_b0010","first-page":"6","article-title":"Inflammation: A two-edged sword-the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"10.1016\/j.ejpb.2022.10.005_b0015","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1378\/chest.08-0776","article-title":"Bronchiectasis","volume":"134","author":"O'Donnell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2022.10.005_b0020","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Martinez-Garcia","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2022.10.005_b0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2022.10.005_b0030","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ejpb.2022.10.005_b0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/17476348.2018.1481392","article-title":"Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis","volume":"12","author":"Athanazio","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.ejpb.2022.10.005_b0040","doi-asserted-by":"crossref","DOI":"10.1111\/resp.13407","article-title":"Emerging therapies in adult and paediatric bronchiectasis","author":"Regan","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ejpb.2022.10.005_b0045","first-page":"147","article-title":"Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD","volume":"4","author":"Giembycz","year":"2010","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejpb.2022.10.005_b0050","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.21037\/jtd.2017.03.116","article-title":"Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases","volume":"9","author":"Kawamatawong","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejpb.2022.10.005_b0055","first-page":"A6255","article-title":"Effect of roflumilast(Daxas) in patients with symptomatic non-cystic fibrosis bronchiectasis. In D51. Non-Cystic fibrosis bronchiectasis","author":"Park","year":"2014","journal-title":"Am. Thorac. Soc."},{"key":"10.1016\/j.ejpb.2022.10.005_b0060","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2125.2007.03089.x","article-title":"Fixed dose drug combinations (FDCs): rational or irrational: a view point","volume":"65","author":"Gautam","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2022.10.005_b0065","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: A meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejpb.2022.10.005_b0070","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Campos, J.L.; Carrasco-Hern\u00e1ndez, L.; Rom\u00e1n Rodr\u00edguez, L.; Quintana-Gallego, E.; Carmona Bernal, C.; Alc\u00e1zar Navarrete, B. The clinical implications of triple therapy in fixed-dose combination in COPD: From the trial to the patient. Arch. Bronconeumol. 2020, 56, 242\u2013248.","DOI":"10.1016\/j.arbr.2020.02.002"},{"key":"10.1016\/j.ejpb.2022.10.005_b0075","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2022.2089111","article-title":"An expert opinion on respiratory delivery of high dose powders for lung infections","author":"Adhikari","year":"2022","journal-title":"Expert Opin. Drug Delivery"},{"key":"10.1016\/j.ejpb.2022.10.005_b0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2018.02.026","article-title":"Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections","volume":"541","author":"Momin","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0085","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3390\/pharmaceutics12080715","article-title":"Co-amorphization of kanamycin with amino acids improves aerosolization","volume":"12","author":"Adhikari","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.10.005_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121799","article-title":"Amino acids improve aerosolization and chemical stability of potential inhalable amorphous spray-dried ceftazidime for Pseudomonas aeruginosa lung infection","volume":"621","author":"Adhikari","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118724","article-title":"Amino acids as stabilizers for spray-dried simvastatin powder for inhalation","volume":"572","author":"Lu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2019.04.036","article-title":"Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying","volume":"565","author":"Lu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0105","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/pharmaceutics13081254","article-title":"Roflumilast powders for chronic obstructive pulmonary disease: Formulation design and the Influence of device, inhalation flow rate, and storage relative humidity on aerosolization","volume":"13","author":"Momin","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.10.005_b0110","article-title":"Optimization of methionine in inhalable high-dose spray-dried amorphous composite particles using response surface method, infrared and low frequency Raman spectroscopy","volume":"614","author":"Adhikari","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00113-L","article-title":"Mechanisms of macromolecule absorption by the lungs","volume":"19","author":"Patton","year":"1996","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2022.10.005_b0120","doi-asserted-by":"crossref","unstructured":"Suzuki \u00c9, Y.; Amaro, M.I.; de Almeida, G.S.; Cabral, L.M.; Healy, A.M.; de Sousa, V.P. Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions. Int. J. Pharm. 2018, 550, 89\u201399.","DOI":"10.1016\/j.ijpharm.2018.08.035"},{"key":"10.1016\/j.ejpb.2022.10.005_b0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/089426803769017659","article-title":"Next generation pharmaceutical impactor (A new impactor for pharmaceutical inhaler testing) Part I: Design","volume":"16","author":"Marple","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.ejpb.2022.10.005_b0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/0091270006294529","article-title":"Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor","volume":"47","author":"Bethke","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2022.10.005_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002040050351","article-title":"Acute inhalation toxicity testing considerations of technical and regulatory aspects","volume":"71","author":"Pauluhn","year":"1996","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejpb.2022.10.005_b0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tiv.2012.10.007","article-title":"In vivo-in vitro comparison of acute respiratory tract toxicity using human 3D airway epithelial models and human A549 and murine 3T3 monolayer cell systems","volume":"27","author":"Sauer","year":"2013","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejpb.2022.10.005_b0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2022.10.005_b0150","unstructured":"Team, R. RStudio: Integrated Development for R, RStudio, Inc., Boston, MA: 2019."},{"key":"10.1016\/j.ejpb.2022.10.005_b0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cis.2015.05.003","article-title":"Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers","volume":"223","author":"Sosnik","year":"2015","journal-title":"Adv. Colloid Interfac."},{"key":"10.1016\/j.ejpb.2022.10.005_b0160","unstructured":"Coates, J. Interpretation of infrared spectra, A practical approach. In Encyclopedia of Analytical Chemistry, McKelvy, R.A.M.a.M.L., Ed. John Wiley & Sons Ltd: New Jersey, United States, 2006."},{"key":"10.1016\/j.ejpb.2022.10.005_b0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molliq.2016.10.009","article-title":"Investigation of inclusion complex of HP-\u03b3-cyclodextrin with ceftazidime","volume":"224","author":"Misiuk","year":"2016","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2022.10.005_b0170","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/molecules17011025","article-title":"Synthesis and preliminary antimicrobial activities of new arylideneamino-1,3,4-thiadiazole-(thio\/dithio)-acetamido cephalosporanic acids","volume":"17","author":"Alwan","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2022.10.005_b0175","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/jps.21033","article-title":"Characterization of the \u201chygroscopic\u201d properties of active pharmaceutical ingredients","volume":"97","author":"Newman","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.10.005_b0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1023\/A:1015932316622","article-title":"Hygroscopicity of Cefazolin Sodium: Application to Evaluate the Crystallinity of Freeze-Dried Products","volume":"5","author":"Osawa","year":"1988","journal-title":"Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists"},{"key":"10.1016\/j.ejpb.2022.10.005_b0185","first-page":"75","article-title":"Hydrophobicity indices for amino acid residues as determined by high-performance liquid chromatography","volume":"3","author":"Cowan","year":"1990","journal-title":"Pept. Res."},{"key":"10.1016\/j.ejpb.2022.10.005_b0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000194839","article-title":"Pulmonary deposition of aerosols by different mechanical devices","volume":"48","author":"Matthys","year":"1985","journal-title":"Respiration"},{"key":"10.1016\/j.ejpb.2022.10.005_b0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1014426530935","article-title":"Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development","volume":"19","author":"Crowder","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.10.005_b0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2016.09.025","article-title":"Effect of ethanol as a co-solvent on the aerosol performance and stability of spray-dried lysozyme","volume":"513","author":"Ji","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaerosci.2007.04.005","article-title":"Particle formation in spray drying","volume":"38","author":"Vehring","year":"2007","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2022.10.005_b0210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11095-004-9020-4","article-title":"How much particle surface corrugation is sufficient to improve aerosol performance of powders?","volume":"22","author":"Chew","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.10.005_b0215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.apt.2012.08.001","article-title":"Dynamic shape factor for particles of various shapes in the intermediate settling regime","volume":"24","author":"Lau","year":"2013","journal-title":"Adv. Powder Technol."},{"key":"10.1016\/j.ejpb.2022.10.005_b0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/archinte.1973.00320070056006","article-title":"Deposition of inhaled aerosols","volume":"131","author":"Stuart","year":"1973","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejpb.2022.10.005_b0225","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/jps.20426","article-title":"Effect of amino acids on the dispersion of disodium cromoglycate powders","volume":"94","author":"Chew","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.10.005_b0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2017.06.004","article-title":"Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis","volume":"528","author":"Momin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jctb.5010020901","article-title":"Ideal copolymers and the second-order transitions of synthetic rubbers. i. non-crystalline copolymers","volume":"2","author":"Gordon","year":"1952","journal-title":"J. Appl. Chem."},{"key":"10.1016\/j.ejpb.2022.10.005_b0240","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0022-3093(81)90047-8","article-title":"A simple derivation of the empirical rule TG\/TM = 2\/3","volume":"44","author":"Kanno","year":"1981","journal-title":"J. Non\u00b7Cryst. Solids"},{"key":"10.1016\/j.ejpb.2022.10.005_b0245","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijpharm.2018.12.036","article-title":"Co-former selection for co-amorphous drug-amino acid formulations","volume":"557","author":"Kasten","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119771","article-title":"Effects of a novel roflumilast and formoterol fumarate dry powder inhaler formulation in experimental allergic asthma","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0255","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejps.2010.03.020","article-title":"Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease","volume":"40","author":"Adi","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.10.005_b0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpharm.2004.07.003","article-title":"Influence of the solvent composition on the aerosol synthesis of pharmaceutical polymer nanoparticles","volume":"284","author":"Raula","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.10.005_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.powtec.2013.06.038","article-title":"Fundamental analysis of particle formation in spray drying","volume":"247","author":"Vicente","year":"2013","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2022.10.005_b0270","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1078-0432.CCR-16-1207","article-title":"Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B-cell malignancies","volume":"23","author":"Kelly","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2022.10.005_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.598702","article-title":"Clinical relevance of the anti-inflammatory effects of roflumilast on human bronchus: Potentiation by a long-acting beta-2-agonist","volume":"11","author":"Salvator","year":"2020","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:52:15Z","timestamp":1760547135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122002302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":55,"alternative-id":["S0939641122002302"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.10.005","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}